Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The company offers human health pharmaceutical for various areas, including oncology, vaccines, hospital acute care, cardiovascular, virology, neuroscience, and diabetes under the Keytruda, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, RotaTeq, Pneumovax 23, Bridion, Dificid, Zerbaxa, Noxafil, Winrevair, Adempas, Verquvo, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. It also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, Bovilis Cryptium, Banamine, Estrumate, Matrix, Resflor, Zuprevo, Revalor, Safe-Guard, M+Pac, Porcilis, Circumvent, Nobilis/Innovax, Paracox and Coccivac, Exzolt, Slice, Imvixa, Clynav, Aquavac/Norvax, Aquaflor, Flexolt brands; Allflex Livestock Intelligence solutions for animal identification, monitoring and traceability; and companion animal products under the Bravecto One-Month, Bravecto Injectable/Quantum, Bravecto Plus, Sentinel Spectrum, Sentinel Flavor Tabs, Optimmune, Nobivac NXT, GilvetMab, Otomax, Mometamax, Mometamax Ultra, Posatex, Caninsulin/Vetsulin, Panacur, Regumate, Prestige, Scalibor/Exspot, Sure Petcare, and Home Again brands. The company has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates; AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types, and Koselugo for multiple indications; licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova; and collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. was founded in 1891 and is headquartered in Rahway, New Jersey.

Merck & Co., Inc.

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Prime Medicine, Inc. (PRME) and Merck & Company (MRK...

Analysts Offer Insights on Healthcare Companies: Prime Medicine, Inc. (PRME) and Merck & Company (MRK)

In a report released on September 21, Trung Huynh from RBC Capital maintained a Hold rating on Merck & Company, with a price target of $150.00. The...

RBC Capital Keeps Their Hold Rating on Merck & Company (MRK)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Merck & Company (MRK), Celldex (CLDX) and Inventiv...

Analysts Offer Insights on Healthcare Companies: Merck & Company (MRK), Celldex (CLDX) and Inventiva (IVA)

Analysts fell to the sidelines weighing in on Merck & Company (MRK) and CVRx (CVRX) with neutral ratings, indicating that the experts are neither b...

Wall Street Analysts Are Neutral on Top Healthcare Picks

Moderna shares ($MRNA) surged by more than 14% to about $176 on Monday afternoon. This came after the U.S. pharma and biotech firm announced a key ...

Why Is Moderna Stock (MRNA) Soaring Today, September 21?

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Merck & Company (MRK), Envista Holdings (NVST) and Ultragenyx Pha...

Analysts Offer Insights on Healthcare Companies: Merck & Company (MRK), Envista Holdings (NVST) and Ultragenyx Pharmaceutical (RARE)

TipRanks’ ETF AI Analyst has an Outperform rating on the Vanguard High Dividend Yield Index ETF ($VYM), Avantis U.S. Large Cap Value ETF ($AVLV), a...

3 ETFs That Could Deliver 10%+ Returns, According to the AI Analyst

Vivmark Residential ( ($VMRK) ) has provided an update. On September 16, 2026, Vivmark Residential’s ERP Operating Limited Partnership raised the m...

Vivmark Residential Expands Commercial Paper Program Capacity

An announcement from Vivmark Residential ( ($VMRK) ) is now available. On September 15, 2026, Vivmark Residential published an updated investor pre...

Vivmark Residential updates outlook, highlights post-merger momentum

RBC Capital analyst Trung Huynh maintained a Hold rating on Merck & Company yesterday and set a price target of $150.00. Huynh covers the Healthcar...

RBC Capital Sticks to Their Hold Rating for Merck & Company (MRK)

U.S. stocks finished Friday higher after declining for four consecutive sessions, as oil prices eased following sharp increases earlier in the week...

The Week That Was, The Week Ahead: Macro and Markets, September 13

DBS analyst Nico Chen maintained a Buy rating on Merck & Company today and set a price target of $180.00. Chen covers the Healthcare sector, focusi...

DBS Keeps Their Buy Rating on Merck & Company (MRK)

Vivmark Residential ( ($VMRK) ) has shared an announcement. Vivmark Residential announced on September 9, 2026 that senior management, including Pr...

Vivmark Residential Highlights Strategy at Global Real Estate Conference

Analysts fell to the sidelines weighing in on Sanofi (SNYNF) and Merck & Company (MRK) with neutral ratings, indicating that the experts are neithe...

Analysts Offer Insights on Healthcare Companies: Sanofi (OtherSNYNF) and Merck & Company (MRK)

Cathie Wood-led ARK Invest made several notable trades on Friday, September 4, with Robinhood Markets ($HOOD), an online brokerage and financial-se...

Cathie Wood Buys $3.6M of HOOD, Sells $2.9M of 2 High-Growth Stocks – September 5

Jefferies analyst James Vane maintained a Hold rating on Merck KGaA today and set a price target of €144.00. According to TipRanks, Vane is an anal...

Jefferies Reaffirms Their Hold Rating on Merck KGaA (0O14)

RedHill Biopharma ($RDHL) divested its Talicia business to Apotex Health Corp. in an $18 million upfront plus potential milestones deal as part of ...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	MRK	$148.67	-0.08%	1.69M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	MRK	$148.67	-0.1%	1.69M
3
4
5
6

MRK

Get Merck & Co., Inc. Data in Excel

Get Merck & Co., Inc. Data in Excel